Skip to content

Correlations Between Arrhythmias and Air Pollution in Patients With Pacemaker and ICD

Correlations Between Arrhythmias, Climatic Variables and Air Pollution in Patients With Pacemaker and ICD, Followed by Remote Monitoring.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01723761
Acronym
ARIA
Enrollment
473
Registered
2012-11-08
Start date
2011-04-30
Completion date
2015-06-30
Last updated
2015-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Arrhythmias

Keywords

air pollution, pacemaker, ICD, remote monitoring, supraventricular arrhythmias, ventricular arrhythmias

Brief summary

It is a clinical, observational study to evaluate the correlations among arrhythmias, climatic variables and air pollution in patients with pacemaker and implantable defibrillator (ICD), followed by remote monitoring. Purpose of the Study: The purpose of this study is to test the hypothesis that changes in climatic variables, such as temperature, pressure and humidity, and changes of particulate matter \<10µ (PM10), particulate matter \<2.5µ (PM2.5), ozone (O3), carbon monoxide (CO), sulfur dioxide (SO2), nitrogen dioxide (NO2), are associated with an increase of supraventricular and ventricular arrhythmias. Objectives: The aim of this study is to determine whether changes in variables conditions affect the electrical stability of the myocardium in patients with pacemakers and ICDs. Population: male and female subjects, aged ≥ 18 years, implanted by a dual-chamber pacemaker, ICD or biventricular ICD (ICD-CRT). A total of 500 subjects from 15 cardiology centers of the Veneto region will be included.

Detailed description

The primary objectives of this study are as follows: * Determine if the changes of temperature, pressure and humidity, are associated with an increase of atrial and ventricular arrhythmias. * Determine if the changes of air pollution (gas and particulate), are associated with an increase of atrial and ventricular arrhythmias. The secondary objectives of the study are: * Determine if the changes of air pollution (gas and particulate), are associated with significant changes in mean heart rate, rate variability rate and the percentage of paced beats. * Determine whether changes in temperature, pressure or humidity, are associated with significant changes in mean heart rate, heart rate variability and the percentage of paced beats. * Determine if the changes of temperature, pressure and humidity, are associated with an increase in mortality or hospitalization for myocardial infarction or congestive heart failure. * Determine if the changes of air pollution (gas and particulate), are associated with an increase in mortality or hospitalization for myocardial infarction or congestive heart failure. Study Design This is a prospective, observational study, which compares the occurrence of atrial and ventricular arrhythmias and changes in physiological parameters, with climatic variables and air pollution. The study will include 500 subjects and will consist of two periods: Screening: we will collect baseline characteristics of subjects in the clinical examination. The period recruitment will run for 12 months. Follow-up: After written informed consent will be signed, subjects who meet the criteria for inclusion will be enrolled in the study and followed up for a minimum period of 12 months. The data obtained from the remote monitoring will be evaluated for the daily values provided for the parameters considered in the study. Periodical visits in pacemaker clinic will be scheduled at the discretion of the referring cardiologist of the center. The arrhythmic events that will occur in this period, detected by means of remote monitoring or through other clinical evaluations will be recorded. Atrial arrythmias: atrial fibrillation or atrial flutter, supraventricular tachycardia. Ventricular arrhythmias: ventricular tachycardia, ventricular fibrillation, ventricular extrasystoles. Physiological variables: average heart rate (24 hours and at rest), heart rate variability, the percentage of paced beats. In addition, any changes in drug therapies and all clinically relevant events, will be recorded. During the same period data from monitoring stations of ARPAV (Regional Agency for Environmental Prevention and Protection of Veneto Region) will be collected. Climatic variables: temperature, humidity, atmospheric pressure. Parameters of air pollution: PM10, PM2.5, O3, CO, SO2, NO2. For each patient, the data from the monitoring station ARPAV of the urban area of residence of the subject will be considered. The mean exposure level used in the analytical studies on the health effects is calculated on the average number of units active in the area. This number is usually of 2-3 units in large centers, while it is generally only 1 in small towns. The residents in centers without monitoring will be excluded from the study. The mean value is the best approximation ... to be continued page 6.

Interventions

None listed

Sponsors

Effect Group, Italy
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Stable subjects,\> 18 years, who have been implanted with a dual-chamber pacemaker, an ICD or ICD-CRT, compatible with remote monitoring systems, with daily transmission of data.

Exclusion criteria

* Presence of heart failure clinically manifest. * Concomitant illness or a significant condition which severely limits the life expectancy. * Any medical or surgical condition that, at the discretion of the investigator, places the patient at higher risk for his participation in the study. * History of malignancy of any organ system in the last two years, whether treated or untreated, including leukemia and lymphoma (with the exception of basal cell carcinoma of the skin) if there is evidence of local recurrence of metastasis. * History of drug or alcohol abuse in the last 2 years. * Participation in another study of a drug or device within 30 days after randomization. * Inability to communicate and to comply with all such obligations including the unwillingness or inability to give an informed consent. * Residence in urban centers without environmental monitoring.

Design outcomes

Primary

MeasureTime frameDescription
incidence of atrial arrhythmias.12- 24 months.The arrhythmic events that will occur during follow-up period, detected by remote monitoring or through other clinical evaluations, will be recorded and classified as follows: atrial fibrillation or atrial flutter, supraventricular tachycardia.
incidence of ventricular arrhythmias12-24 monthsThe arrhythmic events that will occur during follow-up period, detected by remote monitoring or through other clinical evaluations, will be recorded and classified as follows: ventricular tachycardia, ventricular fibrillation, premature ventricular beats.

Secondary

MeasureTime frameDescription
Percentage of paced beats12-24 monthsPercentage of paced beats will be measured by devices diagnostic and obtained via remote monitoring.
Mean heart rate12-24 monthsMean heart rate obtained by remote monitoring of pacemaker and ICDs.
Hospitalization for myocardial infarction or heart failure.12-24 months
Mortality for myocardial infarction or heart failure.12-24 months
Heart rate variability12-24 monthsMeasures of heart rate variability calculated by devices and obtained by remote monitoring.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026